J-Pharma chases Telix in LAT1
But the Japanese group is focused on biliary tract cancer rather than glioblastoma.
Telix sees more backing for LAT1
TLX101 follows Ipax-1 with an apparent success in an academic trial.
Telix heads to the US, as RayzeBio runs into problems
Supply continues to cause headaches for radiopharmaceutical developers.
Astra’s radiopharma Fusion
AstraZeneca's quiet, cautious work is followed by a $2bn takeover.
Bristol makes its radiopharma move
The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.
